The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Forest Laboratories (Inst); GE Healthcare (Inst); Gilead Sciences (Inst); Janssen Scientific Affairs (Inst); Novartis (Inst); Pfizer (Inst); Sunovion (Inst); Teva (Inst); UCB (Inst); Ultragenyx Pharmaceuticals (Inst); Vertex (Inst)
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Forest Laboratories (Inst); GE Healthcare (Inst); Gilead Sciences (Inst); Janssen Scientific Affairs (Inst); Novartis (Inst); Pfizer (Inst); Sunovion (Inst); Teva (Inst); UCB (Inst); Ultragenyx Pharmaceuticals (Inst); Vertex (Inst)
Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for 2nd targeted therapy (TT) of metastatic renal cell carcinoma (mRCC) in the US: A retrospective chart review.
 
James E. Signorovitch
No Relationships to Disclose
 
Sumanta Kumar Pal
Honoraria - Medivation; Novartis
Consulting or Advisory Role - Aveo; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
William M Reichmann
Consulting or Advisory Role - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Forest Laboratories (Inst); GE Healthcare (Inst); Janssen Scientific Affairs (Inst); Novartis (Inst); Novo Nordisk (Inst); Shire (Inst); UCB (Inst)
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Forest Laboratories (Inst); GE Healthcare (Inst); Janssen Scientific Affairs (Inst); Novartis (Inst); Novo Nordisk (Inst); Shire (Inst); UCB (Inst)
 
Nanxin Li
Consulting or Advisory Role - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Forest Laboratories (Inst); Novartis (Inst); Sanofi (Inst)
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Forest Laboratories (Inst); Novartis (Inst); Sanofi (Inst)
 
Zhimei Liu
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Jose Ricardo Perez
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Endocyte; Mannkind; UpToDate
Consulting or Advisory Role - Amgen; AVEO; BIND Biosciences; Janssen Biotech
Speakers' Bureau - Bayer; Caris MPI; Dendreon; GlaxoSmithKline; Medivation; Millennium; Sanofi
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology
 
Eric Jonasch
Consulting or Advisory Role - Genentech/Roche; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Exelixis; GlaxoSmithKline; Novartis; Onyx; Pfizer
Travel, Accommodations, Expenses - GlaxoSmithKline; Novartis; Pfizer